scout
|Videos|June 4, 2019

Results of Niraparib/Bevacizumab Combo in Platinum-Sensitive Recurrent Ovarian Cancer

Mansoor Mirza, MD, chief oncologist, Department of Oncology, Copenhagen University Hospital, discusses the findings from NSGO-AVANOVA2/ENGOT-OV24, the randomized controlled chemotherapy-free study of niraparib (Zejula) and bevacizumab (Avastin) versus niraparib alone in recurrent platinum-sensitive ovarian cancer.

Newsletter

Stay up to date on practice-changing data in community practice.


Latest CME